The Revised Atlanta classification of acute pancreatitis represents the internationally accepted consensus standard for defining, categorizing, and grading the severity of acute inflammatory episodes affecting the pancreas2,5. Originally established in 1992 and subsequently updated in 2012, this classification system resolved longstanding ambiguities in clinical reporting, radiological imaging terminology, and prognostic assessment2,4. By dividing the disease into distinct morphological subtypes (interstitial edematous pancreatitis and necrotizing pancreatitis) and temporal phases (early versus late), the revised framework enables clinicians, radiologists, and surgeons to communicate effectively and guide patient management protocols based on objective physiological and anatomical parameters2,4,5.

Etiology & Risk Factors

  • Gallstone Pancreatitis: The most common etiology worldwide, accounting for approximately 40% to 50% of all cases; caused by transient or persistent obstruction of the ampulla of Vater during biliary microlithiasis or macro-gallstone passage3.
  • Alcohol-Induced Pancreatitis: The second most common etiology, representing 25% to 35% of cases; chronic ethanol consumption sensitizes acinar cells to premature intracellular enzyme activation and oxidative stress.
  • Post-Endoscopic Retrograde Cholangiopancreatography (ERCP): Occurs in 5% to 10% of unselected ERCP procedures, secondary to mechanical manipulation, hydrostatic contrast injection, or thermal injury to the papilla.
  • Metabolic Derangements: Severe hypertriglyceridemia (typically fasting serum triglycerides exceeding 1000 mg/dL or 11.3 mmol/L) and hypercalcemia leading to calcium deposition within the pancreatic parenchyma.
  • Anatomic & Structural Anomalies: Pancreas divisum, pancreatic duct strictures, ampullary neoplasms, and choledocho-pancreatic anomalies that obstruct normal exocrine outflow.
  • Infectious & Toxin-Mediated Agents: Viral pathogens (mumps, coxsackievirus, cytomegalovirus, HIV), bacterial infections (Mycoplasma pneumoniae, Salmonella), and drug-induced toxicities (azathioprine, valproic acid, thiazide diuretics, tetracyclines).
  • Genetic Predispositions: Mutations in the cationic trypsinogen gene (PRSS1), serine protease inhibitor Kazal type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), and chymotrypsinogen C (CTRC) genes.

Pathophysiology

Acute pancreatitis is initiated by intra-acinar activation of digestive enzymes, most notably the conversion of trypsinogen to active trypsin via lysosomal hydrolase cathepsin B. Normally, pancreatic acinar cells protect themselves through trypsinogen cleavage resistance, secretory granule packaging, and high intracellular concentrations of pancreatic secretory trypsin inhibitor (PSTI or SPINK1). When these protective regulatory mechanisms are overwhelmed by noxious stimuli such as gallstones, alcohol metabolites, or ischemia, active trypsin accumulates within the cytoplasm. This triggers the auto-activation of proelastase, phospholipase A2, and carboxypeptidase, resulting in autodigestion of pancreatic acinar cells, ductal epithelium, and surrounding peripancreatic adipose tissue. The resulting cellular injury releases potent damage-associated molecular patterns (DAMPs) that recruit neutrophils and macrophages, activating a massive systemic inflammatory cascade characterized by tumor necrosis factor-alpha (TNF-$\alpha$), interleukin-1 beta (IL-1$\beta$), and interleukin-6 (IL-6). This systemic inflammatory response syndrome (SIRS) increases capillary permeability, causes third-space fluid loss, and drives microvascular thrombosis within the pancreatic microcirculation, accelerating ischemia and driving the transition from mild interstitial edema to extensive pancreatic necrosis3,5.

Revised Atlanta classification of acute pancreatitis — Pathophysiological Cascade & Clinical Flowchart 1 Primary Acinar Insult Gallstone migration, alcohol metabolites, hypercalcemia, or ductal obstruction trigger premature intracellular activation of trypsinogen within pancreatic acinar cells. 2 Inflammatory Cascade Activated trypsin initiates a destructive enzymatic cascade, degrading acinar membranes and releasing cytokines that provoke systemic inflammatory response syndrome (SIRS). 3 Microvascular Injury Capillary endothelial damage leads to interstitial edema, microthrombosis, pancreatic ischemia, and subsequent parenchymal or peripancreatic tissue necrosis. 4 Clinical Manifestation Severe epigastric pain, elevated pancreatic enzymes, systemic shock, and morphological classification into interstitial edematous or necrotizing pancreatitis. 5 Therapeutic Intervention Goal-directed fluid resuscitation, organ support in intensive care units, and step-up surgical or percutaneous catheter drainage for infected necrosis.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients classically present with sudden-onset, severe, constant epigastric or periumbilical abdominal pain that radiates directly through to the back in a "boring" fashion. The pain is frequently ameliorated by leaning forward or assuming a fetal position. Nausea and intractable vomiting are nearly universal, though they rarely relieve the abdominal discomfort. Severe cases may feature progressive dyspnoea due to diaphragmatic irritation, pleural effusions, or acute respiratory distress syndrome.
  • Physical Examination & Named Clinical Signs: Abdominal examination reveals marked epigastric tenderness upon palpation, frequently accompanied by abdominal distension and hypoactive or absent bowel sounds secondary to a paralytic ileus. In severe necrotizing cases, retroperitoneal hemorrhage dissects along tissue planes, producing pathognomonic cutaneous manifestations: Cullen sign (superficial edema and bruising in the subcutaneous fatty tissue around the umbilicus) and Grey Turner sign (bruising of the flanks). Palpable upper abdominal masses may indicate large pancreatic pseudocysts or walled-off necrosis.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationContrast-enhanced computed tomography (CECT) of the abdomen with pancreatic protocol (thin-collimation intravenous contrast-enhanced scans in pancreatic parenchymal and portal venous phases), demonstrating areas of non-enhancing pancreatic parenchyma indicating necrosis or defining peripancreatic fluid collections after 72 hours of symptom onset.
Laboratory PanelSerum lipase levels elevated greater than three times the upper limit of normal ( lipase is preferred over amylase due to higher sensitivity and prolonged elevation window of 8 to 14 days); serum amylase elevated similarly but clears rapidly within 3 to 5 days; complete blood count showing hemoconcentration (hematocrit greater than 44% reflecting intravascular volume depletion) and leukocytosis; comprehensive metabolic panel revealing elevated blood urea nitrogen (BUN) and creatinine (prerenal azotemia), hypocalcemia resulting from saponification of peripancreatic fat, and elevated transaminases (alanine aminotransferase level greater than 150 IU/L strongly suggests a gallstone etiology).
Imaging / Radiology (X-ray, US, CT, MRI)Transabdominal ultrasound performed early to evaluate for gallstone etiology and biliary ductal dilation; abdominal radiography to rule out perforated viscus or identify the "sentinel loop" sign (isolated dilation of a jejunal loop in the left upper quadrant) or "colon cutoff" sign (abrupt termination of gas in the descending colon); magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) utilized to detect occult choledocholithiasis or structural ductal abnormalities when transabdominal ultrasound is inconclusive.
ECG / Histopathology / ProceduralElectrocardiogram (ECG) mandatory upon admission to rule out acute myocardial infarction, which can mimic the severe epigastric pain of acute pancreatitis; histopathological examination (when tissue is available via fine-needle aspiration or surgical resection) reveals coagulative necrosis of pancreatic parenchyma, fat necrosis, saponification, and acute neutrophilic infiltration.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Interstitial Edematous Pancreatitis (IEP)Morphological subtype characterized by diffuse or localized enlargement of the pancreas due to inflammatory edema; uniform enhancement of the pancreatic parenchyma on CECT with no evidence of peripancreatic necrosis; represents 75% to 80% of cases and typically resolves spontaneously within the first week.
Necrotizing PancreatitisMorphological subtype characterized by inflammation associated with pancreatic parenchymal necrosis, peripancreatic necrosis, or both; lacks homogeneous enhancement of the pancreatic parenchyma on CECT; carries a substantially higher risk of infection, multiorgan failure, and mortality.
Mild Acute PancreatitisDefined by the absence of organ failure and the absence of local or systemic complications; patients require supportive care and typically achieve full recovery within the first week without advanced intervention.
Moderately Severe Acute PancreatitisDefined by the presence of transient organ failure (resolving within 48 hours) or local/systemic complications without persistent organ failure; requires closer monitoring, frequently in step-down or high-dependency units.
Severe Acute PancreatitisDefined by persistent organ failure lasting longer than 48 hours involving one or more organ systems (respiratory, cardiovascular, or renal); necessitates intensive care unit admission and multidisciplinary intervention.
Modified Marshall Scoring System for Organ FailureEvaluates three organ systems (respiratory via PaO2/FiO2 ratio, renal via serum creatinine, and cardiovascular via systolic blood pressure/pH); a score of 2 or greater in any single system sustained for greater than 48 hours defines persistent organ failure and severe acute pancreatitis.
Acute Peripancreatic Fluid Collections (APFC)Morphological collection occurring in the early phase (less than 4 weeks) of interstitial edematous pancreatitis, confined to peripancreatic tissue planes without a defined fibrous wall.
Walled-Off Necrosis (WON)A mature, encapsulated collection of pancreatic and/or peripancreatic necrosis with a well-defined inflammatory wall, typically developing more than 4 weeks after the initial onset of necrotizing pancreatitis.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Perforated Peptic UlcerPresents with acute, severe, generalized abdominal pain and board-like rigidity; upright chest or abdominal radiography demonstrates free air under the diaphragm (pneumoperitoneum); pancreatic enzyme levels are typically normal or only mildly elevated.
Acute Cholecystitis & Biliary ColicPain localizes predominantly to the right upper quadrant with a positive Murphy sign; ultrasound reveals gallbladder wall thickening, pericholecystic fluid, and calculi; serum transaminases and bilirubin may be elevated with normal or mildly elevated amylase and lipase.
Acute Mesenteric IschemiaCharacterized by severe, out-of-proportion abdominal pain with minimal initial physical findings; arterial lactate is markedly elevated; computed tomography angiography (CTA) demonstrates occlusion or high-grade stenosis of the celiac axis, superior mesenteric artery, or mesenteric veins.
Acute Myocardial Infarction (Inferior Wall)May present with epigastric pain and vomiting mimicking acute pancreatitis; diagnostic confirmation achieved via 12-lead ECG demonstrating ST-segment elevations in leads II, III, and aVF, accompanied by serial elevation of cardiac troponin I or T.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate aggressive fluid resuscitation is the cornerstone of early management to restore effective circulating blood volume and prevent pancreatic microvascular thrombosis. Administer balanced crystalloids (Lactated Ringer's solution) at an initial rate of 1.5 mL/kg/h to 2.0 mL/kg/h, adjusting infusion rates based on frequent clinical reassessments of vital signs, urine output (greater than 0.5 mL/kg/h), and serial hematocrit measurements. Avoid aggressive fluid boluses in patients with underlying congestive heart failure or end-stage renal disease to prevent iatrogenic volume overload.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Provide adequate analgesia using intravenous opioids, such as hydromorphone (0.2 mg to 1.0 mg IV every 2 to 3 hours as needed) or fentanyl (25 mcg to 50 mcg IV every 1 to 2 hours as needed); traditional concerns regarding morphine-induced sphincter of Oddi spasm have not been shown to worsen clinical outcomes. Initiate early enteral nutrition via a nasogastric or nasojejunal feeding tube within 24 to 48 hours of admission to maintain gut mucosal integrity, decrease bacterial translocation, and reduce infectious complications. Routine prophylactic systemic antibiotics are not recommended for sterile acute pancreatitis, but are indicated for confirmed or highly suspected infected pancreatic necrosis (e.g., meropenem 1 g IV every 8 hours or piperacillin-tazobactam 4.5 g IV every 6 hours).
  • Surgical / Interventional Indications: Interventions (percutaneous catheter drainage, endoscopic transluminal necrosectomy, or surgical debridement) should be delayed for at least 4 weeks when possible to allow peripancreatic collections to mature into walled-off necrosis. Primary indications for intervention include clinically documented or suspected infected necrosis accompanied by persistent sepsis, clinical deterioration despite maximal medical support, or ongoing organ failure failing to resolve.

Complications & Prognosis

  • Local Complications: Include acute peripancreatic fluid collections, pancreatic pseudocysts (defined as collections persisting beyond 4 weeks with a fibrous capsule), acute necrotic collections, and walled-off necrosis. Secondary infection of pancreatic necrosis occurs in up to 30% to 40% of patients with necrotizing pancreatitis and significantly increases mortality. Biliary obstruction, gastric outlet obstruction, and splenic vein thrombosis represent additional structural sequelae.
  • Systemic Complications: Systemic inflammatory response syndrome (SIRS) progressing to multiorgan dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury requiring renal replacement therapy, and disseminated intravascular coagulation (DIC).
  • Prognosis & Mortality: Overall mortality for mild acute pancreatitis is less than 1%. However, in patients who develop severe acute pancreatitis with persistent organ failure and infected necrosis, mortality rates can approach 20% to 30%. Prognosis is dictated primarily by the persistence of organ failure beyond 48 hours and the presence of secondary microbial infection within necrotic pancreatic tissues.